Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$1.32
EPS est.
$1.20
EPS surprise
+10.28%
1-day move
+3.26%
Henry Schein's earnings report shows a strong performance in EPS, exceeding expectations by over 10%. The positive surprise likely contributed to the stock's 3.26% increase in value. However, the lack of revenue data and management commentary leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.32 | $1.22 | +10.28% |
| Revenue | — | $3.3B | — |
No transcript is on record, and the analysis is based on numerical results only.
Henry Schein, Inc. is a leading distributor of health care products and services, primarily serving dental and medical professionals. With a market cap of $8 billion, the company plays a crucial role in the health care supply chain, especially as demand for medical supplies continues to grow amid ongoing health challenges.
Last quarter
In the last quarter, Henry Schein reported an EPS of $1.34, beating estimates by 3.08%. The stock reacted positively, gaining 3.45% the following day.
Management promises and guidance
EPS beat streak
4Q
EPS beat rate
75%
Avg EPS surprise
+3.58%
Avg 1-day reaction
+1.01%
Analysts expect Henry Schein to report solid earnings this quarter, with a consensus EPS of $1.22 and revenue of $3.3 billion. The company has a strong track record of beating earnings estimates.
Bull case
If Henry Schein exceeds expectations, it could indicate robust demand for health care products, leading to increased investor confidence and a potential stock price increase.
Bear case
Conversely, if the company misses estimates, it may raise concerns about market demand and operational challenges, potentially leading to a stock decline.
Key metrics to watch
EPS
$1.22Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$3.3BRevenue figures will provide insight into overall sales performance and demand for health care products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $1.22?
A beat on EPS could reinforce confidence in the company's profitability and operational efficiency.
Q2
What are the revenue projections for the upcoming quarters?
Revenue guidance will be critical in assessing future growth potential and demand for health care products.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the impact of recent product innovations that could drive higher sales than anticipated.
Supporting evidence
The company has a history of beating EPS estimates, which may not be fully priced in.
Recent trends in health care spending suggest stronger demand for products than the consensus reflects.
Key risk
If revenue comes in below $3.3 billion, it could undermine the positive outlook.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on whether Henry Schein can maintain its momentum in a competitive health care market.
Bull confirmed if
An EPS of $1.26 or higher would confirm strong operational performance.
Bear confirmed if
An EPS below $1.16 would raise concerns about demand and profitability.
What the market is pricing for the move.
Implied Move
±6.07%
Historical Avg
±4.6%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±7.9% while HSIC has averaged ±4.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
22.5%
Smart-money positioning from the most recent 13F filings.
Institutional
112.27%
of float
Insider
0.83%
of float
Holders
785
institutions
Top Holders· as of Jun 2026
Kohlberg Kravis Roberts & Co. L.P.
15,652,032 sh · $1.3B
14.04%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Henry Schein beats expectations, history suggests a potential stock increase of around 0.72%, confirming strong demand.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline of about 7.41%, reflecting investor disappointment and concerns over future performance.
The lines on the call that would change the story.
FMR, LLC
7,553,901 sh · $632.0M
6.78%
32.0%
Blackrock Inc.
7,024,663 sh · $587.7M
6.30%
0.0%
Artisan Partners Limited Partnership
6,467,467 sh · $541.1M
5.80%
-1.6%
Vanguard Capital Management LLC
6,346,669 sh · $531.0M
5.69%
-1.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.